Insider Transactions in Q1 2022 at Aclaris Therapeutics, Inc. (ACRS)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2022
|
Neal Walker INTERIM CEO |
SELL
Open market or private sale
|
Direct |
56,303
-4.1%
|
$844,545
$15.91 P/Share
|
|
Mar 10
2022
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
27,165
-16.61%
|
$407,475
$15.71 P/Share
|
|
Mar 10
2022
|
Frank Ruffo Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,823
-5.97%
|
$192,345
$15.55 P/Share
|
|
Mar 02
2022
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,254
+1.31%
|
-
|
|
Mar 02
2022
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,297
+3.72%
|
-
|
|
Mar 02
2022
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+7.1%
|
-
|
|
Mar 01
2022
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
114,425
+4.02%
|
-
|
|
Mar 01
2022
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,050
+7.68%
|
-
|
|
Mar 01
2022
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,750
+18.42%
|
-
|
|
Feb 09
2022
|
Neal Walker INTERIM CEO |
SELL
Open market or private sale
|
Direct |
3,595
-0.29%
|
$43,140
$12.66 P/Share
|
|
Feb 09
2022
|
Frank Ruffo Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,388
-0.8%
|
$16,656
$12.66 P/Share
|
|
Feb 09
2022
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
383
-0.44%
|
$4,596
$12.68 P/Share
|
|
Feb 01
2022
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+0.86%
|
-
|
|
Feb 01
2022
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,875
+2.18%
|
-
|
|
Feb 01
2022
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,050
+1.18%
|
-
|
|
Jan 03
2022
|
Kamil Ali Jackson Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,518
+6.89%
|
-
|